Two Sigma Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-98,200
| Closed | -$12.2M | – | 2425 |
|
|
2025
Q1 | $12.2M | Buy |
98,200
+16,500
| +20% | +$2.15M | 0.03% | 473 |
|
|
2024
Q4 | $10.1M | Sell |
81,700
-24,300
| -23% | -$2.86M | 0.02% | 482 |
|
|
2024
Q3 | $11.8M | Buy |
106,000
+84,500
| +393% | +$9.26M | 0.03% | 444 |
|
|
2024
Q2 | $2.29M | Sell |
21,500
-200
| -0.9% | -$22K | 0.01% | 1116 |
|
|
2024
Q1 | $2.61M | Buy |
21,700
+16,200
| +295% | +$1.98M | 0.01% | 1084 |
|
|
2023
Q4 | $677K | Sell |
5,500
-40,900
| -88% | -$5.1M | ﹤0.01% | 1802 |
|
|
2023
Q3 | $6.01M | Sell |
46,400
-98,400
| -68% | -$13.1M | 0.02% | 650 |
|
|
2023
Q2 | $18M | Sell |
144,800
-46,900
| -24% | -$6.31M | 0.05% | 331 |
|
|
2023
Q1 | $28.1M | Sell |
191,700
-17,500
| -8% | -$2.59M | 0.07% | 255 |
|
|
2022
Q4 | $33.3M | Buy |
209,200
+94,400
| +82% | +$13.8M | 0.09% | 215 |
|
|
2022
Q3 | $15.3M | Buy |
114,800
+65,900
| +135% | +$10M | 0.04% | 389 |
|
|
2022
Q2 | $7.63M | Buy |
48,900
+32,700
| +202% | +$5.03M | 0.02% | 596 |
|
|
2022
Q1 | $2.52M | Buy |
16,200
+9,900
| +157% | +$1.44M | 0.01% | 1120 |
|
|
2021
Q4 | $803K | Buy |
+6,300
| New | +$828K | ﹤0.01% | 1676 |
|
|
2021
Q3 | – | Sell |
-2,400
| Closed | -$426K | – | 2558 |
|
|
2021
Q2 | $426K | Sell |
2,400
-7,985
| -77% | -$1.38M | ﹤0.01% | 2010 |
|
|
2021
Q1 | $1.71M | Buy |
+10,385
| New | +$1.71M | ﹤0.01% | 1352 |
|
|
2020
Q3 | – | Sell |
-36,285
| Closed | -$4M | – | 2521 |
|
|
2020
Q2 | $4M | Buy |
36,285
+11,585
| +47% | +$1.28M | 0.01% | 892 |
|
|
2020
Q1 | $2.46M | Sell |
24,700
-69,485
| -74% | -$8.98M | 0.01% | 1003 |
|
|
2019
Q4 | $14.1M | Buy |
94,185
+59,360
| +170% | +$8.08M | 0.03% | 481 |
|
|
2019
Q3 | $4.46M | Sell |
34,825
-361,285
| -91% | -$48.4M | 0.01% | 807 |
|
|
2019
Q2 | $56.5M | Sell |
396,110
-135,800
| -26% | -$18.3M | 0.14% | 182 |
|
|
2019
Q1 | $76M | Buy |
531,910
+326,300
| +159% | +$42.6M | 0.19% | 132 |
|
|
2018
Q4 | $25.5M | Buy |
205,610
+6,853
| +3% | +$1.02M | 0.07% | 319 |
|
|
2018
Q3 | $33.4M | Sell |
198,757
-37,700
| -16% | -$6.48M | 0.08% | 274 |
|
|
2018
Q2 | $40.7M | Buy |
236,457
+145,300
| +159% | +$23.8M | 0.11% | 227 |
|
|
2018
Q1 | $13.8M | Buy |
91,157
+6,637
| +8% | +$974K | 0.04% | 481 |
|
|
2017
Q4 | $11.4M | Buy |
+84,520
| New | +$11.7M | 0.03% | 557 |
|
|
2017
Q2 | – | Sell |
-157,757
| Closed | -$22.9M | – | 2320 |
|
|
2017
Q1 | $22.9M | Sell |
157,757
-132,375
| -46% | -$17.2M | 0.08% | 335 |
|
|
2016
Q4 | $31.6M | Buy |
290,132
+59,944
| +26% | +$6.68M | 0.12% | 199 |
|
|
2016
Q3 | $28M | Buy |
230,188
+180,803
| +366% | +$24.4M | 0.12% | 197 |
|
|
2016
Q2 | $6.98M | Buy |
49,385
+20,900
| +73% | +$3.08M | 0.04% | 454 |
|
|
2016
Q1 | $3.72M | Sell |
28,485
-22,306
| -44% | -$2.78M | 0.02% | 599 |
|
|
2015
Q4 | $7.14M | Buy |
50,791
+39,680
| +357% | +$5.5M | 0.04% | 383 |
|
|
2015
Q3 | $1.48M | Buy |
+11,111
| New | +$1.91M | 0.01% | 840 |
|
|
2015
Q1 | – | Sell |
-2,200
| Closed | -$360K | – | 2140 |
|
|
2014
Q4 | $360K | Sell |
2,200
-19,900
| -90% | -$3.3M | ﹤0.01% | 1834 |
|
|
2014
Q3 | $3.55M | Sell |
22,100
-156,485
| -88% | -$24.1M | 0.03% | 599 |
|
|
2014
Q2 | $26.3M | Sell |
178,585
-36,900
| -17% | -$5.12M | 0.21% | 115 |
|
|
2014
Q1 | $29.9M | Sell |
215,485
-140,600
| -39% | -$21.2M | 0.27% | 76 |
|
|
2013
Q4 | $45.1M | Buy |
356,085
+273,600
| +332% | +$28.3M | 0.44% | 40 |
|
|
2013
Q3 | $7.59M | Buy |
82,485
+40,100
| +95% | +$3.23M | 0.09% | 235 |
|
|
2013
Q2 | $2.91M | Buy |
+42,385
| New | +$2.59M | 0.04% | 386 |
|
Other funds holding JAZZ
EC
Two Sigma Advisers's JAZZ Position: Q2 2025 in Review
Two Sigma Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 98,200 shares — an estimated $12.2M sold.
Two Sigma Advisers first reported a position in JAZZ in Q2 2013 and held it in 41 quarters. The position peaked at $76M in Q1 2019. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.
- Two Sigma Advisers reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Two Sigma Advisers sold 98,200 Jazz Pharmaceuticals shares in Q2 2025, an estimated $12.2M.
- Two Sigma Advisers first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 41 quarters.
- Two Sigma Advisers's Jazz Pharmaceuticals position peaked at $76M in Q1 2019.
- 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.
Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.